{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 25,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 21,
  "notes": "The slide uses a structured table to segment market opportunity by biological markers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/21",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.06,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Squamous cancer cells with hippo pathway alterations and NF2 mutated cells demonstrate high sensitivity to NXP900 in vitro and in vivo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bacec4a4-98dd-4ee2-b52c-87d589c15b6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.06,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "a. The prevalence of ESCC ex-US is approximately 85%. b. The NF2 mutation is prevalent in approximately 1-3.6 % of patients in several additional solid tumors including breast, NSCLC, ovarian, bladder, melanoma and CRC",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27a9e93f-176f-4d8a-a97f-55fc5eaec866",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.88,
        "x": 0.06,
        "y": 0.2
      },
      "kind": "table",
      "text": "Indication, Estimated Incidence (US), Prevalence, Estimated Addressable Patient Population (US). Rows include Cervical, Esophageal, Metastatic Anal, NSCLC, Head & Neck, Mesothelioma, Papillary Kidney Cancer.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac32ccf1-4d1d-4e80-9361-261009359ae8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXP900 Potential Market Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76c944f8-392b-4264-9696-ea1816926d4a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "1fbd1cc3-2455-425c-a4c2-febb43cab307",
      "evidence": "The slide features a table with estimated incidence, prevalence, and addressable patient population for various indications.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
      "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
      "position": 1,
      "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}